Aurinia to Acquire Kezar Life Sciences for $6.955/Share, Bolstering Autoimmune Pipeline with Zetomipzomib
AUPH has more than doubled off its 52-week low of $6.825.
Summary
Aurinia Pharmaceuticals announced its agreement to acquire Kezar Life Sciences for $6.955 per share in cash, along with potential additional payments and rights to certain proceeds for Kezar shareholders. This strategic acquisition significantly bolsters Aurinia's autoimmune disease pipeline by adding Kezar's lead product candidate, zetomipzomib. Zetomipzomib has shown promising clinical results in autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus, and has had positive interactions with the FDA. This acquisition follows a recent overhaul of Aurinia's executive leadership, signaling a potential new strategic direction for the company. The deal, expected to close in Q2, represents a material expansion of Aurinia's therapeutic offerings and could drive future growth in the autoimmune market. Investors will be watching the successful integration of Kezar's assets and the continued clinical and regulatory progress of zetomipzomib.
At the time of this announcement, AUPH was trading at $14.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $6.83 to $16.54. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.